Abstract: Multiple sclerosis (MS) is more common in women than in men, and it usually occurs in women of childbearing age. Genetic and environmental factors effect the incidence of MS. Greater insight into the underlying pathophysiology of MS has facilitated the development a number of immunomodulatory therapies over the past decade. Oral agents and novel use of monoclonal antibodies are emerging therapies. Improved recognition of common symptoms and the expansion of symptomatic treatments have also improved quality of life for patients with MS. Obstetrician-gynecologists are often operative in longitudinal care and may also identify patients at risk of MS, thereby aiding in the diagnosis.